Nonclinical Study Of The New Immunotropic Drug Effectiveness In Salmonella Infection Treatment

The aim of the study was to evaluate the immunoregulatory activity of an experimental drug based on ultra-high dilutions of antibodies to MHC I and MHC II molecules against Salmonella enteritidis rif92.Materials and methods. The drug tested: a sample of ultra-high water-alcohol dilutions of antibodies to MHC I and MHC II molecules applied to lactose powder (the theoretical level of the initial antibody concentration reduction is at least 10(24) times). A model of non-lethal Salmonella infection in chickens was induced by administering a virulent strain of Salmonella enteritidis rif92 with a concentration of 2.5 x 10(9) CFU/g in the volume of 0.5 ml/bird. The following groups were formed (n = 15 in each group): 1 - drug; 2 - drug + antibiotic at the median effective dose (ED 50); 3 - placebo; 4 - placebo + antibiotic at ED50; 5 - intact control. The duration of the experiment was 12 days. The studied parameters included the survival rate during the observation period; daily body weight; feed consumption for the entire period; pathogen concentration in the litter on day 3, 6, and 9; the presence and concentration of the pathogen in the liver and cecum on day 12; and the index of antimicrobial activity on day 12.Results. In the groups receiving the experimental drug, the infectious process proceeded in a milder form and the bacterial load in chickens was lower. The bacterial count in the litter was reduced by two orders compared to the respective control when the drug was added both alone and in combination with the antibiotic. A protective effect of the experimental drug on the liver of the infected chickens was detected.Conclusion. A pronounced immunoregulatory activity of the studied drug against Salmonella enteritidis rif92 in chickens was demonstrated for the first time. The results obtained allow to consider the drug as a promising agent for the treatment of Salmonella infection.